StageAcquired | Acquired
About Avhana Health
Avhana is a SaaS-based provider of clinical decision support tools that are integrated directly into the electronic health record workflow to help provide real-time, patient-specific best practices at the point of care. On January 13th, 2021, Avhana Health was acquired by Amalgam Rx. The terms of the transaction were not disclosed.
Missing: Avhana Health's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Avhana Health's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Avhana Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Avhana Health is included in 4 Expert Collections, including Value-Based Care & Population Health.
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.
Clinical Encounter Tech
Latest Avhana Health News
Jan 9, 2023
January 9, 2023 Ryan Sysko Amalgam Rx , a digital health startup founded by WellDoc’s Ryan Sysko, has raised $17.4 million in Series A funding from Denmark’s Novo Nordisk, alongside an expanded deal to globally market the Wilmington, Del.-based startup’s digital insulin app Dose Check, according to a listing on Pitchbook. The two companies announced the commercialization deal around Amalgam’s Dose Check, which helps type 2 diabetes patients use basal insulin and manage their medication wirelessly, in the middle of December but did not cite the funding. Founded in 2017, Amalgam has so far raised $18.6 million. It made two key acquisitions in 2021 — Baltimore-based Avhana Health and the assets of Geetha, a developer of conversational AI — as it aims to digitize healthcare. “The future of digital health is in delivering highly personalized, scalable and engaging interventions that learn and adapt over time based on an individual’s needs; big data and AI form the foundation of this future,” Amalgam CEO Ryan Sysko , said, after the company bought Geetha’s assets. Heavyweight Tie-up Denmark-headquartered Novo Nordisk is a pharmaceutical heavyweight with a $140 billion market cap, and has an especially big share of the global diabetes care market. In 2021, it entered into an initial partnership with Amalgam to commercialize Dose Check in some South American markets. Building on the success of that program the two companies late last year decided to expand that partnership to Europe and Asia. Sysko termed that decision “incredibly rewarding and validating,” while Novo Nordisk’s Thomas Thestrup-Terp, corporate vice president for Digital Strategy & Solutions, said the expanded partnership comes “with the ambition to use innovative digital health solutions to further improve personalized care for people living with diabetes.” Other than the partnership with Novo Nordisk, Amalgam has built a portfolio of digital solutions, including patient support programs, therapeutics and digital-pharma combination products. The acquisition of Baltimore-based Avhana brought SaaS-based clinical decision support tools and key integration with electronic health records (EHR) — dubbed the “Holy Grail for digital health solutions” by Sysko. It also helps Amalgam’s path to doctors, simplifying their workflows. Amalgam’s acquisition of Geetha’s assets sets up its prospects for the longer-term future. It brought data science assets, such as more than 6 billion longitudinal data points on millions of patients, along with cutting-edge Natural Language Understanding and Reinforcement Learning and turnkey psychosocial engine in 40 languages, to evaluate personality, moods, and motivators. Geetha’s founder, Bharath Sudharsan, now serves as Amalgam’s chief data scientist and head of AI. citybiz+ Sponsors
Avhana Health Frequently Asked Questions (FAQ)
When was Avhana Health founded?
Avhana Health was founded in 2014.
Where is Avhana Health's headquarters?
Avhana Health's headquarters is located at 8 Market Place, Baltimore.
What is Avhana Health's latest funding round?
Avhana Health's latest funding round is Acquired.
How much did Avhana Health raise?
Avhana Health raised a total of $1.04M.
Who are the investors of Avhana Health?
Investors of Avhana Health include Amalgam Rx, The Maryland Technology Development Corporation, DreamIt Ventures, Boston Millennia Partners, SR One and 5 more.
Who are Avhana Health's competitors?
Competitors of Avhana Health include Stanson Health and 1 more.
Compare Avhana Health to Competitors
EvidenceCare has created an EHR-integrated platform that optimizes clinical workflows to deliver better patient care, improve physicians’ workflow, capture more revenue, and reduce costs. The company was founded in 2014 and is based in Brentwood, Tennessee.
Stanson Health develops CDS solutions. Stanson provides EMR-integrated real time alerts optimized for use in the physician's clinical workflow. Combined with relevant analytics, Stanson solutions safely guide physician decisions toward the elimination of unnecessary or inappropriate care and help improve the quality of care.
National Decision Support is a provider of management platform solutions to healthcare professionals. The company's flagship offering, CareSelect™ Imaging, delivers evidence-based guidelines through an exclusive digital distribution license with the American College of Radiology, and is positioned to help customers meet the federal mandate requiring that clinicians consult Appropriate Use Criteria (AUC) for imaging. NDSC's current portfolio also includes CareSelect Choosing Wisely®, founded on the American Board of Internal Medicine's highly-regarded Choosing Wisely Initiative, and CareSelect Lab, based on a partnership with the Mayo Clinic.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.